

Genevieve Boland, MD, PhD



Society for Immunotherapy of Cancer



Mission & Vision

Mission

Improve cancer patient outcomes by advancing the science, development, and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation, diversity and inclusion, and leadership in the field.

Vision

Make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.





Goals

Education and Scientific Exchange

Serve as the leading resource for information and education on cancer immunotherapy.

Policy and Advocacy

Inform and influence the science, research, regulation, quality of patient care and equity of access impacted by public policy.

Professional Standards

Set industry standards for the field of cancer immunotherapy.

Science and Research

Challenge the thinking, seek and advance the best research to improve outcomes and develop tumor immunology and cancer immunotherapy.

Global Access and Impact

Advance the science and application of, and equitable access to, cancer immunotherapy worldwide.

Leadership Development

Cultivate the next generation of diverse leaders and innovators in tumor immunology and cancer immunotherapy.

SITC Collaborations

Education

- **Advances in Cancer Immunotherapy: A Focus on Surgical Oncology with Society for Surgical Oncology:**
An in person educational session at the SSO annual meeting. In-depth education on all aspects of the clinical implementation of surgical immunotherapy.

Scientific Exchange

- **SITC-ACCC Expanding Access to Cellular Therapies and Bispecifics Workshop:**
A collaborative workshop with the Association of Cancer Care Centers, to identify major hurdles and propose potential solutions to increase access to cellular therapies and bispecifics. The workshop resulted in a meeting report and subsequent webinar.

Policy and Advocacy

- **SITC Quality Measure Development with ASCO:**
SITC contracted with ASCO to assist in the development of 2 quality measures focused on adverse event management and appropriate biomarker testing within the field of immunotherapy. Both measures are now implemented into the CMS MIPS program.

HAPM10 These three areas serve as good examples for two reasons:

1.) They directly relate to one of SITCs' strategic goals.

2.) They each serve as examples of like minded organizations working to gather to fill in gaps that exist within their own membership.

-SSO needed TIL experts and SITC needed an audience

-SITC has Cell therapy experts and ACCC has the individuals actually practicing in the community

-SITC has IO expertise ad ASCO had measure development team in place and audience that will utilize measures in practice.

Miller, Christian (SITC), 2025-03-04T15:29:01.562